Team One Oncology Research

• EPIC: A Phase II Trial of Cemiplimab alone or in combination with Standard of Care Chemotherapy in Locally Advanced or Metastatic Penile Carcinoma. PI: Dr Helen Dearden
• DISCUS: A randomised phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer. PI: Dr Naveen Vasudev
• GUSTO: a multicentre, prospective, open-label, individually randomised, controlled, parallel-group, multi-stage phase II trial of patients with T2-4a N0 M0 MIBC or T(any) N1 M0 MIBC who are suitable for NAC with cisplatin and gemcitabine prior to radical cystectomy. PI: Dr Helen Dearden
• Refine Renal: A multi-arm phase II basket protocol testing reduced intensity immunotherapy across different cancers. PI: Dr Christy Ralph

• Pacific-4: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer. PI: Dr Kevin Franks
• Pacific-8: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy. PI: Dr Mark Teo
• eVolve-MESO: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Malignant Pleural Mesothelioma. PI: Dr Dan Lee
• Refine Lung: A randomised open-label phase III trial of Reduced Frequency pembrolizumab immuNothErapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design. PI: Dr Pooja Jain

• Harmony: A Phase 3 Trial of Fianlimab (REGN3767, ANTI-LAG-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma. PI: Dr Jane Hook
• Immunocore: Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM). PI: Dr Maria Marples
• Impact: Efficacy and safety of first line Cemiplimab in advanced BCC: A phase 2 trial. PI: Dr Shirin Namini
• SCOPE: A Phase 2, Multicentre, Open-Label, Umbrella Study of SCIB1 and iSCIB1+ in Patients with Advanced Unresectable Melanoma Receiving Either Nivolumab with Ipilimumab or SCIB1 with Pembrolizumab. PI: Dr Maria Marples
• MelMarT-II: Melanoma Margins Trial (MelMarT): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma. PI: Dr Howard Peach

• ONC-201: ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. PI: Prof Susan Short
• SPARTA: Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors. PI: Dr Fiona Collinson
• ARISTOCRAT: A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma. PI: Dr Fiona Collinson

ICI-Genetics – Identification of genetic factors that predispose to immune checkpoint inhibitor toxicity. PI: Dr Danny Ullahannan